Clinical Trial Update: A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma [Phase 2]

View source ↗

Summary

This Phase II clinical trial evaluated Velcade (bortezomib) in combination with bendamustine and rituximab for relapsed or refractory follicular lymphoma and ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Rituxan (rituximab)
• Treanda (Bendamustine)
• Velcade (bortezomib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Follicular Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2011-06-22